Monday, April 17, 2017 8:07:50 AM
4/17/17, 6:00 AM
HOUSTON, April 17, 2017 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of William Hahne, MD, to the newly created position of vice president of clinical research. During his career, Dr. Hahne has developed extensive expertise in the management of oncology and hematology drug trials as well as valuable experience managing regulatory applications in the US, Canada and Europe.
Peter Nielsen, chief executive officer of Bio-Path Holdings, commented, “Dr. Hahne’s experience directing clinical research programs, maximizing product pipelines, and managing medical affairs teams make him a valuable addition to our team. We look forward to leveraging his years of experience as we continue to advance our lead oncology candidate, prexigebersen, in its ongoing Phase 2 study, and our next asset, BP1002, into clinical studies later this year.”
Before joining Bio-Path, Dr. Hahne was a medical consultant for a number of organizations including Voisin consulting, Medimmune, Lion Biotechnologies, Seattle Genetics, Aminex Therapeutics, Therakos, and Celgene Cellular Therapeutics. He held executive positions in clinical research and medical affairs at Celator Pharmaceuticals (now a subsidiary of Jazz Pharmaceuticals), Celsion Corp, and CurGen Corp, during which he was integrally involved in the design and management of oncology clinical trials, development of key opinion leaders, and growth of clinical departments to meet needs of advancing pipelines. Earlier, he worked in various clinical and medical positions of increasing responsibility at Glaxo Inc., Marion Merrell Dow, Hoechst Marion Rousel, and Eisai, Inc. Dr. Hahne earned his BA in chemistry from Grinnell College and his MD from Cornell University. He conducted his residency in general surgery at Emory University Affiliated Hospitals in Atlanta, Georgia.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (Liposomal Grb2 antisense), is in a Phase 2 study for blood cancers and in preclinical studies for solid tumors. BP1002 is Bio-Path’s second liposomal antisense drug candidate, and is ready for the clinic where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company's website at www.biopathholdings.com.
Contact Information:
Investors
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
Source: Bio-Path Holdings, In
Recent BPTH News
- Bio-Path Holdings Announces Publication in Biomedicines • GlobeNewswire Inc. • 09/16/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 09:10:15 PM
- Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2024 08:15:26 PM
- Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors • GlobeNewswire Inc. • 08/21/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2024 11:30:23 AM
- Bio-Path Holdings Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/15/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:41:00 PM
- Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024 • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024 • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 10:14:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 10:10:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 10:07:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 09:56:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 12:38:40 PM
- Bio-Path Holdings Provides Clinical Update and Expansion Plans • GlobeNewswire Inc. • 07/08/2024 11:00:00 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/17/2024 12:00:36 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/17/2024 04:15:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 09:10:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 11:18:17 AM
- Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress • GlobeNewswire Inc. • 06/14/2024 11:00:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/11/2024 09:30:47 PM
- Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 06/05/2024 09:46:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 09:20:35 PM
- Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 06/04/2024 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM